Share Price and Basic Stock Data
Last Updated: November 20, 2025, 10:22 pm
| PEG Ratio | 2.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fervent Synergies Ltd operates in the pharmaceuticals sector, with a market capitalization of ₹110 Cr and a stock price of ₹22. The company’s revenue trajectory has shown significant fluctuations over the past few quarters. For instance, sales stood at ₹0.24 Cr in June 2022, which increased dramatically to ₹3.27 Cr in December 2022 before declining again to ₹0.32 Cr in June 2023. However, a notable recovery occurred in December 2023, when sales reached ₹8.83 Cr, followed by an impressive ₹14.85 Cr in March 2024. The trailing twelve months (TTM) revenue was reported at ₹33.09 Cr, indicating a potential upward trend in revenue collection. This growth in sales is critical for the company, especially as it strives to stabilize its operations after experiencing revenue lows in the previous financial year.
Profitability and Efficiency Metrics
Fervent Synergies Ltd’s profitability metrics reveal a mixed performance. The operating profit margin (OPM) stood at 57.35%, reflecting strong operational efficiency compared to industry norms. However, the company has also faced significant profitability challenges, particularly in FY 2024, where the operating profit recorded a loss of ₹13.55 Cr. Despite this setback, the net profit for FY 2025 rebounded to ₹2.95 Cr, translating to an earnings per share (EPS) of ₹0.68. The return on equity (ROE) and return on capital employed (ROCE) both stood at 7.47%, indicating moderate profitability. The interest coverage ratio (ICR) was exceptionally high at 14,935 times, showcasing the company’s ability to meet interest obligations comfortably, a crucial factor for investor confidence.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fervent Synergies Ltd exhibits strong liquidity, with a current ratio of 1,166.31 and a quick ratio of the same value, indicating robust short-term financial health. The company reported no borrowings, which eliminates interest burden and enhances financial stability. The book value per share was ₹11.12, providing a buffer against potential market fluctuations. The price-to-book value (P/BV) ratio stood at 1.99x, suggesting that the stock is trading near its intrinsic value. Additionally, the enterprise value (EV) was recorded at ₹96.89 Cr, which reflects a growing market perception about the company’s future potential. However, the decline in profitability metrics, such as the negative operating profit margin in FY 2024, poses a risk to long-term sustainability.
Shareholding Pattern and Investor Confidence
Fervent Synergies Ltd’s shareholding pattern indicates a strong promoter backing, with promoters holding 74.75% of the total shares, which is significantly higher than public ownership at 25.25%. This concentrated ownership can instill confidence among investors, as it often aligns management interests with shareholder value. The number of shareholders has gradually increased from 2,895 in December 2022 to 3,713 in June 2025, reflecting growing investor interest. However, the decline in promoter shareholding from 73.33% in March 2025 to 71.71% raises concerns about potential dilution. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) further indicates limited institutional interest, which may affect the stock’s liquidity and market perception.
Outlook, Risks, and Final Insight
The outlook for Fervent Synergies Ltd hinges on its ability to sustain revenue growth and improve profitability. The company has demonstrated resilience by recovering from previous financial setbacks, as evidenced by the improved net profit in FY 2025. However, risks remain, including potential fluctuations in sales, as shown by the erratic quarterly revenue patterns, and challenges in maintaining operational efficiency. Additionally, the high dependency on promoter ownership could lead to volatility if management decisions are not aligned with shareholder interests. For investors, the key will be monitoring the company’s ability to convert its operational strengths into sustained profitability while mitigating risks associated with market fluctuation and ownership dilution. A stable trajectory could enhance investor confidence and potentially attract institutional investors in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fervent Synergies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,612 Cr. | 423 | 479/192 | 95.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.2 Cr. | 26.1 | 29.1/17.0 | 91.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,228.23 Cr | 1,183.75 | 53.16 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.24 | 0.23 | 3.27 | 0.89 | 0.32 | 0.32 | 8.83 | 14.85 | 0.34 | 0.39 | 26.33 | 5.40 | 0.68 |
| Expenses | 0.18 | 0.16 | 3.08 | 0.74 | 0.18 | 0.18 | 8.32 | 28.40 | 0.26 | 0.34 | 23.97 | 4.90 | 0.29 |
| Operating Profit | 0.06 | 0.07 | 0.19 | 0.15 | 0.14 | 0.14 | 0.51 | -13.55 | 0.08 | 0.05 | 2.36 | 0.50 | 0.39 |
| OPM % | 25.00% | 30.43% | 5.81% | 16.85% | 43.75% | 43.75% | 5.78% | -91.25% | 23.53% | 12.82% | 8.96% | 9.26% | 57.35% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.05 | 0.06 | 0.18 | 0.14 | 0.13 | 0.13 | 0.50 | -13.60 | 0.07 | 0.04 | 2.35 | 0.49 | 0.38 |
| Tax % | 20.00% | 33.33% | 27.78% | 100.00% | 23.08% | 23.08% | 26.00% | -1.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.05 | 0.05 | 0.14 | 0.00 | 0.10 | 0.09 | 0.37 | -13.41 | 0.07 | 0.04 | 2.35 | 0.50 | 0.38 |
| EPS in Rs | 0.02 | 0.02 | 0.05 | 0.00 | 0.03 | 0.03 | 0.12 | -4.47 | 0.02 | 0.01 | 0.54 | 0.11 | 0.08 |
Last Updated: August 19, 2025, 3:45 pm
Below is a detailed analysis of the quarterly data for Fervent Synergies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.68 Cr.. The value appears to be declining and may need further review. It has decreased from 5.40 Cr. (Mar 2025) to 0.68 Cr., marking a decrease of 4.72 Cr..
- For Expenses, as of Jun 2025, the value is 0.29 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.90 Cr. (Mar 2025) to 0.29 Cr., marking a decrease of 4.61 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.39 Cr.. The value appears to be declining and may need further review. It has decreased from 0.50 Cr. (Mar 2025) to 0.39 Cr., marking a decrease of 0.11 Cr..
- For OPM %, as of Jun 2025, the value is 57.35%. The value appears strong and on an upward trend. It has increased from 9.26% (Mar 2025) to 57.35%, marking an increase of 48.09%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.38 Cr.. The value appears to be declining and may need further review. It has decreased from 0.49 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.11 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.38 Cr.. The value appears to be declining and may need further review. It has decreased from 0.50 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.12 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.08. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.08, marking a decrease of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.63 | 3.51 | 3.67 | 39.15 | 5.51 | 16.67 | 7.35 | 2.21 | 0.68 | 4.63 | 24.31 | 32.46 | 33.09 |
| Expenses | 0.50 | 0.53 | 0.66 | 36.47 | 4.41 | 15.26 | 6.90 | 1.93 | 0.86 | 4.15 | 37.08 | 29.47 | 29.40 |
| Operating Profit | 2.13 | 2.98 | 3.01 | 2.68 | 1.10 | 1.41 | 0.45 | 0.28 | -0.18 | 0.48 | -12.77 | 2.99 | 3.69 |
| OPM % | 80.99% | 84.90% | 82.02% | 6.85% | 19.96% | 8.46% | 6.12% | 12.67% | -26.47% | 10.37% | -52.53% | 9.21% | 11.15% |
| Other Income | -0.04 | 0.00 | -0.07 | 0.83 | 0.06 | 0.41 | 0.03 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.06 | 0.04 | 0.01 | 0.19 | 0.01 | 0.07 | 0.15 | 0.01 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 1.98 | 2.89 | 2.88 | 3.31 | 1.14 | 1.74 | 0.31 | 0.23 | -0.20 | 0.44 | -12.85 | 2.95 | 3.65 |
| Tax % | 32.83% | 32.53% | 33.68% | 27.19% | 27.19% | 28.74% | 25.81% | 26.09% | 20.00% | 47.73% | 0.00% | 0.00% | |
| Net Profit | 1.33 | 1.95 | 1.91 | 2.41 | 0.83 | 1.23 | 0.24 | 0.17 | -0.24 | 0.23 | -12.84 | 2.95 | 3.66 |
| EPS in Rs | 0.53 | 0.65 | 0.64 | 0.80 | 0.28 | 0.41 | 0.08 | 0.06 | -0.08 | 0.08 | -4.28 | 0.67 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 46.62% | -2.05% | 26.18% | -65.56% | 48.19% | -80.49% | -29.17% | -241.18% | 195.83% | -5682.61% | 122.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.67% | 28.23% | -91.74% | 113.75% | -128.68% | 51.32% | -212.01% | 437.01% | -5878.44% | 5805.58% |
Fervent Synergies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | 263% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 65% |
| 3 Years: | 143% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -5% |
| 3 Years: | -8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 3:30 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 42.61 | 46.37 | 66.12 | 131.60 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Inventory Days | 12.16 | 0.00 | 0.00 | 80.66 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Days Payable | 0.00 | 0.00 | ||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 54.77 | 46.37 | 66.12 | 212.26 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Working Capital Days | 1,992.93 | 1,589.99 | 2,337.19 | 256.20 | 1,437.48 | 248.95 | 482.20 | 3,260.23 | 14,331.62 | 2,132.45 | 344.58 | 463.17 |
| ROCE % | 7.48% | 9.09% | 8.02% | 7.51% | 2.79% | 4.28% | 1.08% | 0.56% | -0.46% | 1.02% | -34.81% | 7.47% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.68 | -4.28 | 0.08 | -0.08 | 0.06 |
| Diluted EPS (Rs.) | 0.59 | -4.28 | 0.08 | -0.08 | 0.06 |
| Cash EPS (Rs.) | 0.68 | -4.27 | 0.09 | -0.06 | 0.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Revenue From Operations / Share (Rs.) | 7.42 | 8.10 | 1.54 | 0.22 | 0.73 |
| PBDIT / Share (Rs.) | 0.68 | -4.25 | 0.15 | -0.05 | 0.09 |
| PBIT / Share (Rs.) | 0.67 | -4.27 | 0.14 | -0.06 | 0.08 |
| PBT / Share (Rs.) | 0.67 | -4.28 | 0.14 | -0.06 | 0.07 |
| Net Profit / Share (Rs.) | 0.67 | -4.28 | 0.07 | -0.07 | 0.05 |
| PBDIT Margin (%) | 9.20 | -52.50 | 10.32 | -23.56 | 12.63 |
| PBIT Margin (%) | 9.08 | -52.67 | 9.45 | -29.04 | 10.98 |
| PBT Margin (%) | 9.08 | -52.84 | 9.45 | -29.11 | 10.60 |
| Net Profit Margin (%) | 9.09 | -52.82 | 4.97 | -34.94 | 7.89 |
| Return on Networth / Equity (%) | 6.07 | -42.27 | 0.53 | -0.55 | 0.40 |
| Return on Capital Employeed (%) | 6.05 | -42.00 | 1.01 | -0.45 | 0.56 |
| Return On Assets (%) | 6.05 | -42.08 | 0.52 | -0.55 | 0.39 |
| Asset Turnover Ratio (%) | 0.81 | 0.65 | 0.10 | 0.01 | 0.05 |
| Current Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Quick Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Interest Coverage Ratio (X) | 14935.00 | -304.63 | 2389.00 | -320.60 | 33.04 |
| Interest Coverage Ratio (Post Tax) (X) | 14769.00 | -305.48 | 1152.50 | -474.40 | 21.64 |
| Enterprise Value (Cr.) | 96.89 | 62.69 | 48.33 | 44.11 | 39.38 |
| EV / Net Operating Revenue (X) | 2.99 | 2.58 | 10.44 | 64.84 | 17.81 |
| EV / EBITDA (X) | 32.44 | -4.91 | 101.15 | -275.19 | 140.94 |
| MarketCap / Net Operating Revenue (X) | 2.99 | 2.58 | 10.48 | 65.27 | 20.11 |
| Price / BV (X) | 1.99 | 2.06 | 1.12 | 1.03 | 1.03 |
| Price / Net Operating Revenue (X) | 2.99 | 2.58 | 10.49 | 65.49 | 20.11 |
| EarningsYield | 0.03 | -0.20 | 0.00 | -0.01 | 0.00 |
After reviewing the key financial ratios for Fervent Synergies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.68, marking an increase of 4.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.59, marking an increase of 4.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 3. It has increased from -4.27 (Mar 24) to 0.68, marking an increase of 4.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.42. It has decreased from 8.10 (Mar 24) to 7.42, marking a decrease of 0.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 2. It has increased from -4.25 (Mar 24) to 0.68, marking an increase of 4.93.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.27 (Mar 24) to 0.67, marking an increase of 4.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 2. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For PBDIT Margin (%), as of Mar 25, the value is 9.20. This value is below the healthy minimum of 10. It has increased from -52.50 (Mar 24) to 9.20, marking an increase of 61.70.
- For PBIT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.67 (Mar 24) to 9.08, marking an increase of 61.75.
- For PBT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.84 (Mar 24) to 9.08, marking an increase of 61.92.
- For Net Profit Margin (%), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from -52.82 (Mar 24) to 9.09, marking an increase of 61.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 15. It has increased from -42.27 (Mar 24) to 6.07, marking an increase of 48.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.05. This value is below the healthy minimum of 10. It has increased from -42.00 (Mar 24) to 6.05, marking an increase of 48.05.
- For Return On Assets (%), as of Mar 25, the value is 6.05. This value is within the healthy range. It has increased from -42.08 (Mar 24) to 6.05, marking an increase of 48.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.65 (Mar 24) to 0.81, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 3. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Quick Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 2. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14,935.00. This value is within the healthy range. It has increased from -304.63 (Mar 24) to 14,935.00, marking an increase of 15,239.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14,769.00. This value is within the healthy range. It has increased from -305.48 (Mar 24) to 14,769.00, marking an increase of 15,074.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 96.89. It has increased from 62.69 (Mar 24) to 96.89, marking an increase of 34.20.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 32.44. This value exceeds the healthy maximum of 15. It has increased from -4.91 (Mar 24) to 32.44, marking an increase of 37.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.99, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -0.20 (Mar 24) to 0.03, marking an increase of 0.23.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fervent Synergies Ltd:
- Net Profit Margin: 9.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.05% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.07% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 14769
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1166.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30 (Industry average Stock P/E: 53.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/7-8, Satyam Shopping Centre, Mumbai Maharashtra 400077 | info@ferventsynergies.com http://www.ferventsynergies.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay P Thakkar | Chairman |
| Mr. Sanjay P Thakkar | Managing Director |
| Mr. Karan Thakkar | Director & CFO |
| Mr. Nitin Parikh | Independent Director |
| Mr. Rajesh Maheshwari | Independent Director |
| Mrs. Falguni Mehta | Independent Director |